DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $433,000 | -99.6% | 1,709 | -99.6% | 0.01% | -98.7% |
| Q3 2021 | $121,358,000 | +13.7% | 398,628 | +0.2% | 0.47% | -65.0% |
| Q2 2021 | $106,777,000 | +13.7% | 397,888 | -4.6% | 1.33% | +27.3% |
| Q1 2021 | $93,874,000 | +16.7% | 417,070 | +15.2% | 1.05% | +10.8% |
| Q4 2020 | $80,434,000 | -26.9% | 362,089 | -29.2% | 0.94% | -44.1% |
| Q3 2020 | $110,054,000 | +20.9% | 511,096 | -0.7% | 1.69% | -7.2% |
| Q2 2020 | $91,013,000 | +28.9% | 514,694 | +0.9% | 1.82% | -4.3% |
| Q1 2020 | $70,595,000 | -3.3% | 510,044 | +7.3% | 1.90% | +40.3% |
| Q4 2019 | $72,979,000 | +0.7% | 475,496 | -5.2% | 1.36% | +4.2% |
| Q3 2019 | $72,472,000 | -3.3% | 501,778 | -4.3% | 1.30% | -5.9% |
| Q2 2019 | $74,927,000 | -15.0% | 524,261 | -21.5% | 1.38% | -23.1% |
| Q1 2019 | $88,137,000 | +27.6% | 667,605 | -0.4% | 1.80% | +4.8% |
| Q4 2018 | $69,088,000 | -5.4% | 669,973 | -0.4% | 1.71% | +65.5% |
| Q3 2018 | $73,065,000 | +11.5% | 672,421 | +1.2% | 1.04% | +13.9% |
| Q2 2018 | $65,549,000 | +14.0% | 664,262 | +13.1% | 0.91% | +5.7% |
| Q1 2018 | $57,487,000 | +23.5% | 587,139 | +17.0% | 0.86% | +50.1% |
| Q4 2017 | $46,560,000 | +7.6% | 501,621 | -0.6% | 0.57% | -0.2% |
| Q3 2017 | $43,290,000 | +2.2% | 504,666 | +0.5% | 0.57% | +13.7% |
| Q2 2017 | $42,374,000 | +1.0% | 502,119 | +2.4% | 0.50% | +4.3% |
| Q1 2017 | $41,939,000 | +10.8% | 490,347 | +0.8% | 0.48% | +21.6% |
| Q4 2016 | $37,853,000 | -1.4% | 486,298 | -0.7% | 0.40% | +5.9% |
| Q3 2016 | $38,389,000 | -21.3% | 489,720 | +1.4% | 0.38% | -30.9% |
| Q2 2016 | $48,784,000 | +5.5% | 483,014 | -0.9% | 0.54% | +13.8% |
| Q1 2016 | $46,245,000 | +2.8% | 487,508 | +0.6% | 0.48% | +10.1% |
| Q4 2015 | $44,991,000 | -36.7% | 484,401 | -41.9% | 0.43% | -33.6% |
| Q3 2015 | $71,099,000 | -9.2% | 834,401 | -8.8% | 0.65% | +21.8% |
| Q2 2015 | $78,288,000 | +1.8% | 914,687 | +0.9% | 0.54% | -4.6% |
| Q1 2015 | $76,932,000 | +5.1% | 906,153 | +6.1% | 0.56% | +1.6% |
| Q4 2014 | $73,203,000 | +25.5% | 854,074 | +11.2% | 0.55% | +18.1% |
| Q3 2014 | $58,344,000 | -2.1% | 767,892 | +1.4% | 0.47% | -1.3% |
| Q2 2014 | $59,614,000 | +5.2% | 757,194 | +0.2% | 0.48% | -4.0% |
| Q1 2014 | $56,676,000 | +39.2% | 755,676 | +43.3% | 0.50% | +48.2% |
| Q4 2013 | $40,725,000 | +6.5% | 527,522 | -4.3% | 0.33% | +18.0% |
| Q3 2013 | $38,227,000 | +10.1% | 551,457 | +0.5% | 0.28% | +10.1% |
| Q2 2013 | $34,726,000 | – | 548,600 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |